Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Davis Polk Advises ShockWave Medical, Inc. on Its $111.4 Million Initial Public Offering
Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock…
Horizon Pharma Follow-On Offering
Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma…
Medtronic Global Holdings S.C.A. €7 Billion Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €7…
Merck $5 Billion Notes Offering
Davis Polk advised the representatives of the underwriters in connection with the offering of $5.0 billion aggregate…
Davis Polk Advises CStone Pharmaceuticals on Its HK$2.24 Billion (US$285.05 Million) Initial Public Offering
Davis Polk advised CStone Pharmaceuticals in connection with its initial public offering and listing on the Hong Kong Stock…
Davis Polk Advises Roche on Its Acquisition of Spark Therapeutics
Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction,…
Eli Lilly $4.5 Billion Notes Offering
Davis Polk advised the joint book-running managers in connection with a $4.5 billion registered offering by Eli Lilly and…
Pernix Enters into an Agreement for the Sale of Substantially All of Its Assets Subject to a Competitive Bidding Process and Files for Chapter 11
Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the…
Sienna Biopharmaceuticals, Inc. $20 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $20 million SEC-registered common stock offering by…
Alector, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of…